Validated markers assessing long-COVID symptoms were improved in a clinically meaningful manner with enhanced external counterpulsation (EECP) according to findings presented at The American College of Cardiology Cardiovascular Summit Virtual (CV Summit) held virtually on February 17-19, 2022. Approximately 6 months after SARS-CoV-2 infection acute phase, 50% of patients worldwide have lingering symptoms. EECP is known to improve cerebral and cardiac perfusion, and is a noninvasive technique that researchers sought to evaluate as a novel therapy for long-COVID symptoms in patients with and without coronary artery disease.
As many as 50% of people who recover from COVID-19 may experience a constellation of such symptoms, and there's not much that doctors can do for these patients because long COVID is such a new entity.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the coronavirus disease 2019 (COVID-19) pandemic. As patients recover from COVID-19, some continue to report persisting symptoms weeks to months after acute infection. These effects have been referred to as post-acute sequelae of SARS-CoV-2 infection (PASC). We report the case of a 38-year-old woman suffering from PASC symptoms following acute COVID-19 in October 2020. During her acute infection phase, she had a home recovery and reported her predominant symptoms as fatigue, headaches, body pain, and shortness of breath. After most of her symptoms were resolved, she continued to have periodic episodes of fatigue and headaches, along with random shortness of breath while at rest and during activities for months beyond the acute phase of the illness.
She also noted the presence of "brain fog," as if lacking the same clarity that she had prior to her illness. These symptoms persisted for three months before the patient underwent enhanced external counterpulsation (EECP) therapy in one-hour sessions, three times per week. This therapy was chosen based on the mechanism of action of EECP benefiting patients with ischemic cardiovascular diseases. After one week, her "brain fog" had improved, with shortness of breath improving after 1.5 weeks. The patient reported returning to pre-COVID health and fitness after approximately five weeks of EECP treatment. To our knowledge, this is the first case of using EECP for post-COVID
ECP improves blood circulation naturally, so it also helps relieve symptoms or diseases caused by poor blood flow, we call these sub-health problems: